MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.35 3.05

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.34

Max

1.35

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+102.27% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-8.4M 73M
Vorheriger Eröffnungskurs	-1.7
Vorheriger Schlusskurs	1.35

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2026, 04:27 UTC

Wichtige Nachrichtenereignisse

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. Apr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 18:30 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. Apr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. Apr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. Apr. 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. Apr. 2026, 16:50 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. Apr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 16:12 UTC

Ergebnisse

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2026, 15:20 UTC

Wichtige Nachrichtenereignisse

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. Apr. 2026, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. Apr. 2026, 14:11 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. Apr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. Apr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. Apr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Apr. 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. Apr. 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. Apr. 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. Apr. 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. Apr. 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

102.27% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 102.27%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.